The drug candidate, depemokimab, was measured in severe asthma patients with Type 2 inflammation characterized by blood eosinophil count, GSK said in a May 21 news release. Compared to a placebo, study participants who took depemokimab experienced fewer asthma attacks over 52 weeks.
The biologic is designed to be administered twice a year, and it’s the first ultra-long-acting severe asthma treatment to be tested in a phase 3 trial, the release said. GSK said it plans to share more data at an upcoming conference and file for regulatory approval.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
